(Q35196447)

7 August 2017

1 reference

title

The importance of insulin resistance in polycystic ovary syndrome (English)

1 reference

polycystic ovary syndrome

7 August 2017

1 reference

1 reference

1 reference

1 reference

1

Mark O Goodarzi

1 reference

7 August 2017

Stanley G Korenman

2

1 reference

PubMed ID

12909480

7 August 2017

language of work or name

English

0 references

publication date

1 August 2003

1 reference

7 August 2017

Fertility and Sterility

1 reference

7 August 2017

80

1 reference

7 August 2017

2

1 reference

7 August 2017

255-258

1 reference

Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome

7 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2900734-9

Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2900734-9

Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2900734-9

Effects of metformin on adrenal steroidogenesis in women with polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2900734-9

A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2900734-9

Limitations of the fasting glucose to insulin ratio as an index of insulin sensitivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2900734-9

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2900734-9

Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2900734-9

Insulin action in the polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2900734-9

Polycystic Ovary Syndrome (PCOS): Arguably the Most Common Endocrinopathy Is Associated with Significant Morbidity in Women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2900734-9

The importance of diagnosing the polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2900734-9

The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2900734-9

Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2900734-9

Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2900734-9

Hyperinsulinemia in polycystic ovary syndrome correlates with increased cardiovascular risk independent of obesity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2900734-9

Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2900734-9

Glucose intolerance in obese adolescents with polycystic ovary syndrome: roles of insulin resistance and beta-cell dysfunction and risk of cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2900734-9

Polycystic ovary syndrome--long-term metabolic consequences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2900734-9

Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2900734-9

Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2900734-9

Low grade chronic inflammation in women with polycystic ovarian syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2900734-9

The plasminogen activator system in women with polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2900734-9

The plasma homocysteine levels are increased in polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2900734-9

Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2900734-9

Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2900734-9

Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2900734-9

Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2900734-9

Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2900734-9

Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2900734-9

Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2900734-9

Lipid and apolipoprotein abnormalities in hirsute women. I. The association with insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2900734-9

Cardiovascular risk continuum: implications of insulin resistance and diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2900734-9

A two-step model for development of non-insulin-dependent diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2900734-9

Relation of functional ovarian hyperandrogenism to non-insulin dependent diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2900734-9

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2900734-9

Long or highly irregular menstrual cycles as a marker for risk of type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2900734-9

Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2900734-9

Pharmacologic therapy for type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2900734-9

Improved endothelial function with metformin in type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2900734-9

Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2900734-9

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2900734-9

Metformin improves ovulation and pregnancy rates in patients with polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2900734-9

Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2900734-9

Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2900734-9

Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2900734-9

Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2900734-9

Effects of metformin on early pregnancy loss in the polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2900734-9

10.1016/S0015-0282(03)00734-9

7 January 2021

Identifiers

DOI

1 reference

7 August 2017

1 reference

PubMed ID

12909480